Mexican drug regulator imposes Rs 28 lakh penalty on Dr Reddy's Labs
Hyderabad: Dr Reddy's Labs has said in the BSE filing that the drug regulatory body of Mexico (Comisión Federal para la Protección contra Riesgos Sanitarios or Cofepris) has imposed a penalty of Rs 28 Lakh on the Company for deviation from prescribed guidelines for filing intimation of import of a reference standard for one of the active pharmaceutical ingredients (APIs).
Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe
Read also: USFDA completes inspection at Dr Reddy's Labs Bachupally RnD centre
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.